Navigation Links
Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
Date:7/18/2011

CAMBRIDGE, England, July 19, 2011 /PRNewswire/ --


Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.

LSR is a common neuropathic pain condition caused by compression of the nerve roots in the lumbar region of the spine. Common features include pain radiating from the lower back down the legs, together with sensory and motor impairment in the lower limbs. LSR is a very high unmet medical need, affecting 3-5% of the global population and there are no drug treatments currently approved for treating this type of neuropathic pain.[1]

The Phase II trial is a randomised, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of orally administered CNV1014802 in patients with pain associated with LSR. It is an innovative study, incorporating a number of design features which will enhance confidence in the outcome of the study. The trial will run in four European countries and results are expected in the second half of 2012.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, added: "We are delighted to announce the start of this trial; the second clinical stage trial initiated since our conception as a Company in October 2011 and a testament to our innovative team. It is clear that safe, effective pain treatment is urgently required and we are focussed on driving forward the development of our pipeline to meet this need."

Commenting on the announcement, Simon Tate, Chief Scientific Officer of Convergence Pharmaceuticals, said: "We are very excited to be initiating this Phase II study for CNV1014802.  CNV1014802's differentiated and superior profile could have a significant impact on the treatment of patients with
'/>"/>

SOURCE Convergence Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Rahal Letterman Lanigan Racing (RLL) and StemCyte, ... cell banking and therapeutics, announced today that StemCyte has ... Stairlifts Indy car driven by James Jakes ... IZOD IndyCar 2013 season.   StemCyte, Inc. and ... awareness of umbilical cord blood banking and its educational ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 The New ... STEM industries, Black Data Processing Associates (BDPA), is hosting ... June 8, 2013. This all-day event will encourage students ... learn the ins and outs from many of the ... p.m. at the New Jersey Institute of Technology, the ...
(Date:5/23/2013)... Tucson, Ariz. (PRWEB) May 23, 2013 ... world’s first and only FDA, Health Canada and CE ... Glasgow Science Centre in Scotland, which boasts more than ... Total Artificial Heart powered by the Freedom® portable ... one of the most advanced exhibitions of its kind. ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... Call on U.S. Senate to Take Similar Action, ... of America (ATA), the industry trade organization for ... Appropriations,Subcommittee for taking action that if adopted by ... Homeland Security (DHS) US-VISIT,Exit program., The House-approved ...
... ... FUNCTIONAL FOOD market-- LAVAL, QC, Sept. 25 /PRNewswire-FirstCall/ - ... it entered a worldwide alliance with Marine Life Sciences who ... distribution,of dietary supplements and functional food products in the global,nutraceutical ...
... for the year increase approximately 13.5% vs. prior year, ... Board: CONX), a worldwide developer and marketer of,diagnostic test ... reported,financial results. The report disclosed that the company,s sales ... June 30, 2008.,Some of the results highlighted by the ...
Cached Biology Technology:Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition 2Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition 3Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition 4Corgenix Reports Fiscal 2008 Financial Results 2Corgenix Reports Fiscal 2008 Financial Results 3Corgenix Reports Fiscal 2008 Financial Results 4
(Date:5/22/2013)... YORK CITY, May 22, 2013 U.S. Forest Service ... team that, with funding from the TKF Foundation, will ... help communities and individuals recover from tragedy. , The ... one of six projects selected for grant funding. In ... and sacred spaces in recovery and resiliency, the 3-year, ...
(Date:5/22/2013)... physicists have developed a novel technique that can detect ... process that is one of the most important, though ... in a paper in Nature , post-doctoral researcher ... Melanie Schnell of the Center for Free-Electron Laser Science ... on finely-tuned microwave fields to identify molecular variants apart, ...
(Date:5/22/2013)... approach to genetic engineering drastically reduces the time ... bacteria, the workhorses of biotechnology, scientists are reporting. ... , the method paves the way for more ... environmental cleanup and other activities. , Keith Shearwin ... piece of the genetic material DNA into a ...
Breaking Biology News(10 mins):'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
... a scientific team from Beth Israel Deaconess Medical Center (BIDMC) ... known as large intervening non-coding RNAs or "lincRNAs," a discovery ... of these molecules in many biological processes, including stem cell ... But even as one question was being answered, another ...
... early-life experience sticks with them into adulthood and may render ... aging, according to a new UBC study. A team ... genome-wide profiling in 103 healthy adults aged 25-40 years. ... high in early-life socioeconomic circumstances related to income, education and ...
... Va.The Journal of Vascular and Interventional Radiology ,s quality ... years, and the increase in its impact factor to 2.217 ... radiology, nuclear medicine and medical imaging journals, according to results ... continues to see a rise in its impact, the Society ...
Cached Biology News:LincRNAs serve as genetic air-traffic controllers 2LincRNAs serve as genetic air-traffic controllers 3Early-life experience linked to chronic diseases later in life: UBC research 2Journal of Vascular and Interventional Radiology increases impact, international reach 2Journal of Vascular and Interventional Radiology increases impact, international reach 3
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
... perfusion system. For real-time or pre-programmed ... electrochemistry, or general liquid-handling research applications. ... accuracy Run experiments automatically - ... and flexibility Turnkey perfusion system ...
... GenBank Accession Number : NM_006225 ... fusion protein corresponding to full length rat ... 7.4, 0.15M NaCl, 0.05% sodium azide before ... Assurance: routinely evaluated by immunoblot on RIPA ...
...
Biology Products: